Microscopic yeast have been wreaking havoc in hospitals around the world—creeping into catheters, ventilator tubes, and IV lines—and causing deadly invasive infection. One culprit species, Candida auris, is resistant to many antifungals, meaning once a person is infected, there are limited treatment options. But in a recent Antimicrobial Agents and Chemotherapy study, researchers confirmed a new drug compound kills drug-resistant C. auris, both in the laboratory and in a mouse model that mimics human infection.
APX001, the prodrug of the active moiety APX001A, is currently in clinical development by Amplyx Pharmaceuticals. It works through a novel mechanism of action. Unlike other antifungal agents that poke holes in yeast cell membranes or inhibit sterol synthesis, the new drug targets an enzyme called Gwt1, which is required for anchoring critical proteins to the fungal cell wall. This means C. auris can’t grow properly and has a harder time forming drug-resistant fungal biofilms that are a stubborn source of hospital outbreaks. Gwt1 is highly conserved across fungal species, suggesting the new drug could treat a broad range of fungal infections.
“The drug is first in a new class of antifungals, which could help stave off drug resistance. Even the most troublesome strains are unlikely to have developed workarounds for its mechanism of action,” said study lead Mahmoud A. Ghannoum, PhD, professor of dermatology at Case Western Reserve University School of Medicine and director of the Center for Medical Mycology at Case Western Reserve University and University Hospitals Cleveland Medical Center.
In the new study, Ghannoum’s team tested the drug against 16 different C. auris strains, collected from infected patients in Germany, Japan, South Korea, and India. When they exposed the isolates to the new drug, they found it more potent than nine other currently available antifungals. According to the authors, the concentration of study drug needed to kill C. auris growing in laboratory dishes was “eight-fold lower than the next most active drug, anidulafungin, and more than 30-fold lower than all other compounds tested.”
The researchers also developed a new mouse model of invasive C. auris infection for the study. Said Ghannoum, “To help the discovery of effective drugs it will be necessary to have an animal model that mimics this infection. Our work helps this process in two ways: first we developed the needed animal model that mimics the infection caused by this devastating yeast, and second, we used the developed model to show the drug is effective in treating this infection.”
Ghannoum studied immunocompromised mice infected with C. auris via their tail vein—similar to very sick humans in hospitals who experience bloodstream infections. Infected mice treated with APX001 and anidulafungin had significant reductions in kidney and lung fungal burden two days post-treatment, compared to control animals. APX001 also significantly decreased fungal burden in the brain, consistent with brain penetration, whereas reduction with anidulafungin did not reach significance. The results suggest the new drug could help treat even the most invasive infections.
According to Ghannoum, the most exciting element of the study is that it brings a promising antifungal one step closer to patients. It helps lay the foundation for phase 2 clinical trials that study that study the safety and efficacy of new drugs in patients with fungal infections. There is an urgent need for such studies, as C. auris infection has become a serious threat to healthcare facilities worldwide—and resistance to commercially available antifungal drugs is rising.
“Limited treatment options calls for the development of new drugs that are effective against this devastating infection,” Ghannoum said. “We hope that we contributed in some way towards the development of new drugs.”
The Latest on: Antifungal
via Google News
The Latest on: Antifungal
- Author Nikita Upadhyay shares some easy-to-do at home beauty hacks for millennialson August 17, 2019 at 12:52 am
Turmeric: A reigning queen of spices in the Ayurveda queen, turmeric is loaded with antibacterial, antiviral and antifungal properties. It also helps to lower the density of bad cholesterol, to keep ...
- Nonprofit under pressure to make new TB drug affordableon August 15, 2019 at 9:16 am
The pathway aims to address unmet medical needs by advancing antibacterial and antifungal drugs for serious infections that affect a limited number of patients. Authorities warn that ...
- Structural design of microbicidal cationic oligomers and their synergistic interaction with azoles against Candida albicanson August 15, 2019 at 2:34 am
Azoles, more specifically triazoles, are currently the most widely used and studied class of antifungal agents. To achieve enhanced efficacy, the interaction of our synthetic oligomers with ...
- Global Antifungal Agents Market Analysis 2019- Asperqillus, Alternaria, Abbott Laboratorieson August 14, 2019 at 7:46 pm
Aug 14, 2019 (Eon Market Research via COMTEX) -- A research report added to the repository of eonmarketresearch.com details the historical data of the global Antifungal Agents market and assesses the ...
- FDA Approves New Treatment for Highly Drug-Resistant Forms of Tuberculosison August 14, 2019 at 9:52 am
1 The new drug was approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD pathway) as part of a three-drug, six-month, all-oral regimen for the treatment of ...
- CorMedix Inc. Reports Second Quarter and Six Month 2019 Financial Results and Provides Business Updateon August 13, 2019 at 5:32 pm
Presented at the FDA public meeting on the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) hearing held on July 12, 2019. Dr. Phoebe Mounts, Esq, CorMedix Executive Vice ...
- Cidara Therapeutics Reports Positive Topline Results in Phase 2 STRIVE B Trial of Antifungal Rezafunginon August 13, 2019 at 5:30 pm
SAN DIEGO, July 29, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing novel anti-infectives, including immunotherapies, today reported positive topline ...
- Amphotericin Bon August 12, 2019 at 6:17 am
Amphotericin B is an antifungal antibiotic produced by the bacterium Streptomyces nodosus. In 1955, it was isolated from soil collected near the Orinoco River of Venezuela by researchers at the Squibb ...
- The proteins that maintain formicamycin biosynthesis fidelityon August 12, 2019 at 5:57 am
Tests showed that isolated formicapyridines do not display antifungal or antibacterial activity. So why are they produced? The team who discovered the formicapyridines, led by Professor's Barrie ...
via Bing News